​

Polyrizon Stock (NASDAQ:PLRZ)

FinancialsChart
Polyrizon by TradingView

Previous Close

$1.07

52W Range

$0.55 - $1.20K

50D Avg

$1.09

200D Avg

$84.29

Market Cap

$6.53M

Avg Vol (3M)

$1.27M

Beta

-4.96

Div Yield

-

PLRZ Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

2

IPO Date

Oct 29, 2024

Website

PLRZ Performance

PLRZ Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-1.30M$-635.00K$-895.00K
Net Income$-1.54M$-600.00K$-779.00K
EBITDA$-1.18M$-594.00K$-772.00K
Basic EPS-$-0.16$-0.20
Diluted EPS-$-0.16$-0.20

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
ALZNAlzamend Neuro, Inc.
XTLBXTL Biopharmaceuticals Ltd.
ADXNAddex Therapeutics Ltd
NRSNNeuroSense Therapeutics Ltd.
PMCBPharmaCyte Biotech, Inc.
BCLIBrainstorm Cell Therapeutics Inc.
VYNEVYNE Therapeutics Inc.
QLGNQualigen Therapeutics, Inc.
TCRTAlaunos Therapeutics, Inc.